Cipla Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has ninety-two approved drugs.
There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and thirty-four supplementary protection certificates in seventeen countries.
Summary for Cipla
International Patents: | 30 |
US Patents: | 6 |
Tradenames: | 81 |
Ingredients: | 81 |
NDAs: | 92 |
Patent Litigation for Cipla: | See patent lawsuits for Cipla |
PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cipla | CELECOXIB | celecoxib | CAPSULE;ORAL | 207446-003 | Sep 23, 2015 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cipla | PREGABALIN | pregabalin | CAPSULE;ORAL | 212280-008 | Jan 10, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cipla | FLUTAMIDE | flutamide | CAPSULE;ORAL | 075780-001 | Sep 19, 2001 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cipla Ltd | ZIDOVUDINE | zidovudine | CAPSULE;ORAL | 078349-001 | May 23, 2007 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cipla | METOPROLOL SUCCINATE | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 207465-003 | Oct 26, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20100110297 | ⤷ Try a Trial |
European Patent Office | 3150617 | ⤷ Try a Trial |
South Korea | 101296099 | ⤷ Try a Trial |
Japan | 2011504508 | ⤷ Try a Trial |
Canada | 2669727 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cipla Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1419152 | 132012902054377 | Italy | ⤷ Try a Trial | PRODUCT NAME: EMTRICITABINA/RILPIVIRINA CLORIDRATO/TENOFOVIR DISOPROXIL FUMARATO(EVIPLERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/737/001-002, 20111128 |
2487163 | 2016/062 | Ireland | ⤷ Try a Trial | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; REGISTRATION NO/DATE: EU/1/15/1025 20160713 |
1419152 | PA2012009 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: EMTRICITABINUM + RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28 EU/1/11/737/002 20111128 |
0388054 | SPC/GB05/022 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DARIFENACIN HYDROBROMIDE; REGISTERED: UK EU/1/04/294/001 20041022; UK EU/1/04/294/002 20041022; UK EU/1/04/294/003 20041022; UK EU/1/04/294/004 20041022; UK EU/1/04/294/005 20041022; UK EU/1/04/294/006 20041022; UK EU/1/04/294/007 20041022; UK EU/1/04/294/008 20041022; UK EU/1/04/294/009 20041022; UK EU/1/04/294/010 20041022; UK EU/1/04/294/011 20041022; UK EU/1/04/294/012 20041022 |
0801067 | C00801067/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |